Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced injury.
Liver ischemia followed by reperfusion results in liver injury which in turn produces and releases destructive proinflammatory cytokines into the circulation causing subsequent damage to other organs. This remains a significant problem for surgical procedures and liver transplantation.


OBJECTIVE
In this study, we show the effect of rosuvastatin on multiple organ dysfunction induced by hepatic/ischemia reperfusion.


METHODS
Hepatic ischemia and reperfusion (I/R) injury was induced in rats, and groups of rats were pretreated with oral rosuvastatin.


RESULTS
Our study detected the levels of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), IL-10, and monocyte chemotactic protein 1 (MCP-1) not only in serum but also in liver, lung, kidney intestine, and heart tissues. Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-α, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production.


CONCLUSIONS
This is the first report of rosuvastatin immunomodulatory effects on multiorgan dysfunction after hepatic I/R. Our data suggest a therapeutic potential for rosuvastatin in attenuating inflammation and modulating immune response independent of lipid lowering effect.
Awad
Azza S
AS
Department of Pharmacology & toxicology, Faculty of Pharmacy, Al-Azhar university, Nasr City, Cairo, Egypt.
El Sharif
Amany
A
D000818:Animals; D001769:Blood / Q000187:drug effects / Q000378:metabolism; D018932:Chemokine CCL2 / Q000097:blood / Q000378:metabolism; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D007155:Immunologic Factors / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000097:blood / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000378:metabolism
C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D005464:Fluorobenzenes; D007155:Immunologic Factors; D015850:Interleukin-6; D011743:Pyrimidines; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000068718:Rosuvastatin Calcium